Drug

Tislelizumab

Tislelizumab: highest development phase Phase 3, developed by BeiGene, Natera, United Therapeutics and others. 22 trial records tracked on RxWires.

Trials

Drug	Phase	Indication
Tislelizumab NCT03957590	Phase 3	Esophageal Squamous Cell Carcinoma (ESCC)
Tislelizumab NCT04005716	Phase 3	Small Cell Lung Cancer
Tislelizumab NCT04921358	Phase 3	Non-Small Cell Lung Cancer (NSCLC)
Tislelizumab NCT04379635	Phase 3	Non Small Cell Lung Cancer
Tislelizumab NCT03412773	Phase 3	Hepatocellular Carcinoma (HCC)
Tislelizumab NCT06332274	Phase 3	Cancer
Tislelizumab NCT03777657	Phase 3	Gastric, or Gastroesophageal Junction Adenocarcinoma
Tislelizumab NCT04866017	Phase 3	Non Small Cell Lung Cancer
Tislelizumab NCT03594747	Phase 3	Non-Small Cell Lung Cancer
Tislelizumab NCT04746924	Phase 3	Non-small Cell Lung Cancer
Tislelizumab NCT05116085	Phase 2	Colorectal Cancer
Tislelizumab NCT03469557	Phase 2	Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Tislelizumab NCT03209973	Phase 2	Classical Hodgkin Lymphoma
Tislelizumab NCT04732494	Phase 2	Esophageal Squamous Cell Carcinoma
Tislelizumab NCT03432598	Phase 2	Locally Advanced Lung Cancer; Metastatic Lung Cancer
Tislelizumab, AVD, Radiotherapy NCT05627115	Phase 2	Hodgkin Lymphoma
Tislelizumab NCT07290985	Phase 2	Gastroesophageal Adenocarcinoma
Tislelizumab NCT05366829	Phase 2	Carcinoma, Hepatocellular
Tislelizumab NCT03419897	Phase 2	Hepatocellular Carcinoma (HCC)
Tislelizumab NCT07136077	Phase 2	Minimal Residual Disease
Tislelizumab (BGB-A317) NCT03736889	Phase 2	MSI-H/dMMR Solid Tumors
Tislelizumab IV NCT06091943	Phase 1	Non-small Cell Lung Cancer

No recent events.

Follow Tislelizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.